Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer

Sheta,Razan; Bachvarova,Magdalena; Plante,Marie; Gregoire,Jean; Renaud,Marie-Claude; Sebastianelli,Alexandra; Popa,Ion; Bachvarov,Dimcho

doi:10.3892/ijo.2017.4147

Altered expression of different GalNAc‑transferases is associated with disease progression and poor prognosis in women with high-grade serous ovarian cancer

Authors:
- Razan Sheta
- Magdalena Bachvarova
- Marie Plante
- Jean Gregoire
- Marie-Claude Renaud
- Alexandra Sebastianelli
- Ion Popa
- Dimcho Bachvarov
View Affiliations

Affiliations: Department of Molecular Medicine, Laval University, Quebec, Quebec G1V 0A6, Canada, CHU de Québec Research Center, Hotel-Dieu de Québec, Quebec, QC G1R 3S3, Canada, Molecular Biology, Medical Biochemistry, and Pathology, Laval University, QC G1V 0A6, Canada
Published online on: October 9, 2017 https://doi.org/10.3892/ijo.2017.4147
Pages: 1887-1897

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Protein glycosylation perturbations are implicated in a variety of diseases, including cancer. Aberrant glycosylation in cancer is frequently attributed to altered expression of polypeptide GalNAc transferases (GalNAc‑Ts) - enzymes initiating mucin-type O-glycosylation. A previous study from our group demonstrated that one member of this family (GALNT3) is overexpressed in epithelial ovarian cancer (EOC), and GALNT3 expression correlated with shorter progression-free survival (PFS) in EOC patients with advanced disease. As considerable degree of redundancy between members of the GalNAc‑Ts gene family has been frequently observed, we decided to investigate whether other members of this family are essential in EOC progression. In silico analysis based on publically available data was indicative for altered expression of five GalNAc‑Ts (GALNT2, T4, T6, T9 and T14) in ovarian high-grade serous carcinoma (HGSC) samples compared to non-tumoral (control) ovarian tissue. We analyzed protein expression of these GalNAc‑Ts in EOC cells and tumors by western blotting, followed by immunohistochemical (IHC) evaluation of their expression in EOC tumor and control samples using tissue microarrays (TMAs). Western blot analyses were indicative for low expression of GALNT2 and strong expression of GALNT6, T9 and T14 in both EOC cells and tumors. These observations were confirmed by IHC. GALNT2 displayed significantly lower expression, while GALNT6, GALNT9 and GALNT14 showed significantly higher expression in HGSC tumors compared to control tissue. Importantly, GALNT6 and GALNT14 expression correlated with poor prognosis of serous EOC patients. Moreover, our results suggest for overlapping functions of some GalNAc‑Ts, more specifically GALNT3 and GALNT6, in directing EOC progression. Our results are indicative for a possible implication of different members of the GalNAc‑T gene family in modulating EOC progression, and the potential use of GALNT6 and GALNT14 as novel prognostic EOC biomarkers. These data warrant future studies on the role of members of the GalNAc‑Ts gene family in ovarian tumorigenesis.

View Figures

View References

1	Siegel R, Ward E, Brawley O and Jemal A: Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 61:212–236. 2011. View Article : Google Scholar : PubMed/NCBI
2	Fruscio R, Corso S, Ceppi L, Garavaglia D, Garbi A, Floriani I, Franchi D, Cantù MG, Bonazzi CM, Milani R, et al: Conservative management of early-stage epithelial ovarian cancer: Results of a large retrospective series. Ann Oncol. 24:138–144. 2013. View Article : Google Scholar
3	Alouini S: Management of ovarian cancer has changed. Gynecol Oncol. 126:313author reply 314. 2012. View Article : Google Scholar : PubMed/NCBI
4	Pinho SS and Reis CA: Glycosylation in cancer: Mechanisms and clinical implications. Nat Rev Cancer. 15:540–555. 2015. View Article : Google Scholar : PubMed/NCBI
5	Stowell SR, Ju T and Cummings RD: Protein glycosylation in cancer. Annu Rev Pathol. 10:473–510. 2015. View Article : Google Scholar : PubMed/NCBI
6	Abbott KL: Glycomic analysis of ovarian cancer: Past, present, and future. Cancer Biomark. 8:273–280. 2011. View Article : Google Scholar
7	Sheta R and Bachvarov D: Role of aberrant glycosylation in ovarian cancer dissemination. Biomedecial Rev. 25:83–92. 2014. View Article : Google Scholar
8	Tabak LA: The role of mucin-type O-glycans in eukaryotic development. Semin Cell Dev Biol. 21:616–621. 2010. View Article : Google Scholar : PubMed/NCBI
9	Ten Hagen KG, Fritz TA and Tabak LA: All in the family: the UDP-GalNAc:polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 13:1R–16R. 2003. View Article : Google Scholar : PubMed/NCBI
10	Hang HC and Bertozzi CR: The chemistry and biology of mucin-type O-linked glycosylation. Bioorg Med Chem. 13:5021–5034. 2005. View Article : Google Scholar : PubMed/NCBI
11	Bennett EP, Mandel U, Clausen H, Gerken TA, Fritz TA and Tabak LA: Control of mucin-type O-glycosylation: A classification of the polypeptide GalNAc-transferase gene family. Glycobiology. 22:736–756. 2012. View Article : Google Scholar :
12	Bennett EP, Hassan H, Mandel U, Mirgorodskaya E, Roepstorff P, Burchell J, Taylor-Papadimitriou J, Hollingsworth MA, Merkx G, van Kessel AG, et al: Cloning of a human UDP-N-acetyl-alpha-D-Galactosamine:polypeptide N-acetylgalactosaminyltransferase that complements other GalNAc-transferases in complete O-glycosylation of the MUC1 tandem repeat. J Biol Chem. 273:30472–30481. 1998. View Article : Google Scholar : PubMed/NCBI
13	Beaman EM and Brooks SA: The extended ppGalNAc-T family and their functional involvement in the metastatic cascade. Histol Histopathol. 29:293–304. 2014.
14	Brooks SA, Carter TM, Bennett EP, Clausen H and Mandel U: Immunolocalisation of members of the polypeptide N-acetylgalactosaminyl transferase (ppGalNAc-T) family is consistent with biologically relevant altered cell surface glycosylation in breast cancer. Acta Histochem. 109:273–284. 2007. View Article : Google Scholar : PubMed/NCBI
15	Wang ZQ, Bachvarova M, Morin C, Plante M, Gregoire J, Renaud MC, Sebastianelli A and Bachvarov D: Role of the polypeptide N-acetylgalactosaminyltransferase 3 in ovarian cancer progression: Possible implications in abnormal mucin O-glycosylation. Oncotarget. 5:544–560. 2014. View Article : Google Scholar : PubMed/NCBI
16	Sheta R, Woo CM, Roux-Dalvai F, Fournier F, Bourassa S, Droit A, Bertozzi CR and Bachvarov D: A metabolic labeling approach for glycoproteomic analysis reveals altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells. J Proteomics. 145:91–102. 2016. View Article : Google Scholar : PubMed/NCBI
17	Sheta R, Roux-Dalvai F, Woo CM, Fournier F, Bourassa S, Bertozzi CR, Droit A and Bachvarov D: Proteomic dataset for altered glycoprotein expression upon GALNT3 knockdown in ovarian cancer cells. Data Brief. 8:342–349. 2016. View Article : Google Scholar : PubMed/NCBI
18	Taylor PT and Haverstick D: Re: New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Cancer Inst. 97:151author reply 152. 2005. View Article : Google Scholar : PubMed/NCBI
19	Elgaaen BV, Olstad OK, Sandvik L, Odegaard E, Sauer T, Staff AC and Gautvik KM: ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival. PLoS One. 7:e463172012. View Article : Google Scholar : PubMed/NCBI
20	Marth JD: Complexity in O-linked oligosaccharide biosynthesis engendered by multiple polypeptide N-acetylgalactosaminyltransferases. Glycobiology. 6:701–705. 1996. View Article : Google Scholar : PubMed/NCBI
21	Dube DH and Bertozzi CR: Glycans in cancer and inflammation-potential for therapeutics and diagnostics. Nat Rev Drug Discov. 4:477–488. 2005. View Article : Google Scholar : PubMed/NCBI
22	Hakomori S: Glycosylation defining cancer malignancy: New wine in an old bottle. Proc Natl Acad Sci USA. 99:10231–10233. 2002. View Article : Google Scholar : PubMed/NCBI
23	Christiansen MN, Chik J, Lee L, Anugraham M, Abrahams JL and Packer NH: Cell surface protein glycosylation in cancer. Proteomics. 14:525–546. 2014. View Article : Google Scholar
24	Fuster MM and Esko JD: The sweet and sour of cancer: Glycans as novel therapeutic targets. Nat Rev Cancer. 5:526–542. 2005. View Article : Google Scholar : PubMed/NCBI
25	Wang R, Yu C, Zhao D, Wu M and Yang Z: The mucin-type glycosylating enzyme polypeptide N-acetylgalactosaminyltransferase 14 promotes the migration of ovarian cancer by modifying mucin 13. Oncol Rep. 30:667–676. 2013. View Article : Google Scholar : PubMed/NCBI
26	Lin MC, Huang MJ, Liu CH, Yang TL and Huang MC: GALNT2 enhances migration and invasion of oral squamous cell carcinoma by regulating EGFR glycosylation and activity. Oral Oncol. 50:478–484. 2014. View Article : Google Scholar : PubMed/NCBI
27	Ho WL, Chou CH, Jeng YM, Lu MY, Yang YL, Jou ST, Lin DT, Chang HH, Lin KH, Hsu WM, et al: GALNT2 suppresses malignant phenotypes through IGF-1 receptor and predicts favorable prognosis in neuroblastoma. Oncotarget. 5:12247–12259. 2014. View Article : Google Scholar : PubMed/NCBI
28	Wu YM, Liu CH, Hu RH, Huang MJ, Lee JJ, Chen CH, Huang J, Lai HS, Lee PH, Hsu WM, et al: Mucin glycosylating enzyme GALNT2 regulates the malignant character of hepatocellular carcinoma by modifying the EGF receptor. Cancer Res. 71:7270–7279. 2011. View Article : Google Scholar : PubMed/NCBI
29	Liu SY, Shun CT, Hung KY, Juan HF, Hsu CL, Huang MC and Lai IR: Mucin glycosylating enzyme GALNT2 suppresses malignancy in gastric adenocarcinoma by reducing MET phos-phorylation. Oncotarget. 7:11251–11262. 2016. View Article : Google Scholar : PubMed/NCBI
30	Wright PK, May FE, Darby S, Saif R, Lennard TW and Westley BR: Estrogen regulates vesicle trafficking gene expression in EFF-3, EFM-19 and MCF-7 breast cancer cells. Int J Clin Exp Pathol. 2:463–475. 2009.PubMed/NCBI
31	Niang B, Jin L, Chen X, Guo X, Zhang H, Wu Q, Padhiar AA, Xiao M, Fang D and Zhang J: GalNAc-T4 putatively modulates the estrogen regulatory network through FOXA1 glycosylation in human breast cancer cells. Mol Cell Biochem. 411:393–402. 2016. View Article : Google Scholar
32	Zhang J, Zhang Z, Wang Q, Xing XJ and Zhao Y: Overexpression of microRNA-365 inhibits breast cancer cell growth and chemoresistance through GALNT4. Eur Rev Med Pharmacol Sci. 20:4710–4718. 2016.PubMed/NCBI
33	Liu Y, Liu W, Xu L, Liu H, Zhang W, Zhu Y, Xu J and Gu J: GALNT4 predicts clinical outcome in patients with clear cell renal cell carcinoma. J Urol. 192:1534–1541. 2014. View Article : Google Scholar : PubMed/NCBI
34	Li Z, Yamada S, Wu Y, Wang KY, Liu YP, Uramoto H, Kohno K and Sasaguri Y: Polypeptide N-acetylgalactosaminyltransferase-6 expression independently predicts poor overall survival in patients with lung adenocarcinoma after curative resection. Oncotarget. 7:54463–54473. 2016. View Article : Google Scholar : PubMed/NCBI
35	Freire-de-Lima L, Gelfenbeyn K, Ding Y, Mandel U, Clausen H, Handa K and Hakomori SI: Involvement of O-glycosylation defining oncofetal fibronectin in epithelial-mesenchymal transition process. Proc Natl Acad Sci USA. 108:17690–17695. 2011. View Article : Google Scholar : PubMed/NCBI
36	Tarhan YE, Kato T, Jang M, Haga Y, Ueda K, Nakamura Y and Park JH: Morphological changes, cadherin switching, and growth suppression in pancreatic cancer by GALNT6 knockdown. Neoplasia. 18:265–272. 2016. View Article : Google Scholar : PubMed/NCBI
37	Gomes J, Marcos NT, Berois N, Osinaga E, Magalhães A, Pinto-de-Sousa J, Almeida R, Gärtner F and Reis CA: Expression of UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 in gastric mucosa, intestinal metaplasia, and gastric carcinoma. J Histochem Cytochem. 57:79–86. 2009. View Article : Google Scholar :
38	Liesche F, Kölbl AC, Ilmer M, Hutter S, Jeschke U and Andergassen U: Role of N-acetylgalactosaminyltransferase 6 in early tumorigenesis and formation of metastasis. Mol Med Rep. 13:4309–4314. 2016. View Article : Google Scholar : PubMed/NCBI
39	Park JH, Nishidate T, Kijima K, Ohashi T, Takegawa K, Fujikane T, Hirata K, Nakamura Y and Katagiri T: Critical roles of mucin 1 glycosylation by transactivated polypeptide N-acetylgalactosaminyltransferase 6 in mammary carcinogenesis. Cancer Res. 70:2759–2769. 2010. View Article : Google Scholar : PubMed/NCBI
40	Park JH, Katagiri T, Chung S, Kijima K and Nakamura Y: Polypeptide N-acetylgalactosaminyltransferase 6 disrupts mammary acinar morphogenesis through O-glycosylation of fibronectin. Neoplasia. 13:320–326. 2011. View Article : Google Scholar : PubMed/NCBI
41	Berois N, Mazal D, Ubillos L, Trajtenberg F, Nicolas A, Sastre-Garau X, Magdelenat H and Osinaga E: UDP-N-acetyl-D-galactosamine: Polypeptide N-acetylgalactosaminyltransferase-6 as a new immunohistochemical breast cancer marker. J Histochem Cytochem. 54:317–328. 2006. View Article : Google Scholar
42	Freire T, Berois N, Sóñora C, Varangot M, Barrios E and Osinaga E: UDP-N-acetyl-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 6 (ppGalNAc-T6) mRNA as a potential new marker for detection of bone marrow-disseminated breast cancer cells. Int J Cancer. 119:1383–1388. 2006. View Article : Google Scholar : PubMed/NCBI
43	Patani N, Jiang W and Mokbel K: Prognostic utility of glycosyltransferase expression in breast cancer. Cancer Genomics Proteomics. 5:333–340. 2008.
44	Kölbl AC, Hiller RA, Ilmer M, Liesche F, Heublein S, Schröder L, Hutter S, Friese K, Jeschke U and Andergassen U: Glycosyltransferases as marker genes for the quantitative polymerase chain reaction-based detection of circulating tumour cells from blood samples of patients with breast cancer undergoing adjuvant therapy. Mol Med Rep. 12:2933–2938. 2015. View Article : Google Scholar : PubMed/NCBI
45	Pangeni RP, Channathodiyil P, Huen DS, Eagles LW, Johal BK, Pasha D, Hadjistephanou N, Nevell O, Davies CL, Adewumi AI, et al: The GALNT9, BNC1 and CCDC8 genes are frequently epigenetically dysregulated in breast tumours that metastasise to the brain. Clin Epigenetics. 7:572015. View Article : Google Scholar : PubMed/NCBI
46	Berois N, Gattolliat CH, Barrios E, Capandeguy L, Douc-Rasy S, Valteau-Couanet D, Bénard J and Osinaga E: GALNT9 gene expression is a prognostic marker in neuroblastoma patients. Clin Chem. 59:225–233. 2013. View Article : Google Scholar
47	Tuupanen S, Hänninen UA, Kondelin J, von Nandelstadh P, Cajuso T, Gylfe AE, Katainen R, Tanskanen T, Ristolainen H, Böhm J, et al: Identification of 33 candidate oncogenes by screening for base-specific mutations. Br J Cancer. 111:1657–1662. 2014. View Article : Google Scholar : PubMed/NCBI
48	Keita M, Wang ZQ, Pelletier JF, Bachvarova M, Plante M, Gregoire J, Renaud MC, Mes-Masson AM, Paquet ÉR and Bachvarov D: Global methylation profiling in serous ovarian cancer is indicative for distinct aberrant DNA methylation signatures associated with tumor aggressiveness and disease progression. Gynecol Oncol. 128:356–363. 2013. View Article : Google Scholar
49	Huanna T, Tao Z, Xiangfei W, Longfei A, Yuanyuan X, Jianhua W, Cuifang Z, Manjing J, Wenjing C, Shaochuan Q, et al: GALNT14 mediates tumor invasion and migration in breast cancer cell MCF-7. Mol Carcinog. 54:1159–1171. 2015. View Article : Google Scholar
50	Wu C, Guo X, Wang W, Wang Y, Shan Y, Zhang B, Song W, Ma S, Ge J, Deng H, et al: N-Acetylgalactosaminyltransferase-14 as a potential biomarker for breast cancer by immunohistochemistry. BMC Cancer. 10:1232010. View Article : Google Scholar : PubMed/NCBI
51	Kwon OS, Oh E, Park JR, Lee JS, Bae GY, Koo JH, Kim H, Choi YL, Choi YS, Kim J, et al: GalNAc-T14 promotes metastasis through Wnt dependent HOXB9 expression in lung adenocarcinoma. Oncotarget. 6:41916–41928. 2015. View Article : Google Scholar : PubMed/NCBI
52	Wagner KW, Punnoose EA, Januario T, Lawrence DA, Pitti RM, Lancaster K, Lee D, von Goetz M, Yee SF, Totpal K, et al: Death-receptor O-glycosylation controls tumor-cell sensitivity to the proapoptotic ligand Apo2L/TRAIL. Nat Med. 13:1070–1077. 2007. View Article : Google Scholar : PubMed/NCBI
53	Wu C, Shan Y, Liu X, Song W, Wang J, Zou M, Wang M and Xu D: GalNAc-T14 may be involved in regulating the apoptotic action of IGFBP-3. J Biosci. 34:389–395. 2009. View Article : Google Scholar : PubMed/NCBI
54	Liang KH, Lin CL, Chen SF, Chiu CW, Yang PC, Chang ML, Lin CC, Sung KF, Yeh C, Hung CF, et al: GALNT14 genotype effectively predicts the therapeutic response in unresectable hepatocellular carcinoma treated with transcatheter arterial chemoembolization. Pharmacogenomics. 17:353–366. 2016. View Article : Google Scholar : PubMed/NCBI
55	Lin WR, Chiang JM, Liang KH, Lim SN, Lai MW, Tsou YK, Hsieh TY, Hsu CK and Yeh CT: GALNT14 genotype predicts postoperative outcome of stage III colorectal cancer with oxaliplatin as adjuvant chemotherapy. Medicine (Baltimore). 95:e34872016. View Article : Google Scholar
56	Liang KH, Lin CC and Yeh CT: GALNT14 SNP as a potential predictor of response to combination chemotherapy using 5-FU, mitoxantrone and cisplatin in advanced HCC. Pharmacogenomics. 12:1061–1073. 2011. View Article : Google Scholar : PubMed/NCBI
57	Soria JC, Márk Z, Zatloukal P, Szima B, Albert I, Juhász E, Pujol JL, Kozielski J, Baker N, Smethurst D, et al: Randomized phase II study of dulanermin in combination with paclitaxel, carboplatin, and bevacizumab in advanced non-small-cell lung cancer. J Clin Oncol. 29:4442–4451. 2011. View Article : Google Scholar : PubMed/NCBI
58	Thorburn A, Behbakht K and Ford H: TRAIL receptor-targeted therapeutics: Resistance mechanisms and strategies to avoid them. Drug Resist Updat. 11:17–24. 2008. View Article : Google Scholar : PubMed/NCBI
59	Bennett EP, Hassan H, Mandel U, Hollingsworth MA, Akisawa N, Ikematsu Y, Merkx G, van Kessel AG, Olofsson S and Clausen H: Cloning and characterization of a close homologue of human UDP-N-acetyl-alpha-D-galactosamine:Polypeptide N-acetylgalactosaminyltransferase-T3, designated GalNAc-T6. Evidence for genetic but not functional redundancy. J Biol Chem. 274:25362–25370. 1999. View Article : Google Scholar : PubMed/NCBI
60	Li Z, Yamada S, Inenaga S, Imamura T, Wu Y, Wang KY, Shimajiri S, Nakano R, Izumi H, Kohno K, et al: Polypeptide N-acetylgalactosaminyltransferase 6 expression in pancreatic cancer is an independent prognostic factor indicating better overall survival. Br J Cancer. 104:1882–1889. 2011. View Article : Google Scholar : PubMed/NCBI
61	Kitada S, Yamada S, Kuma A, Ouchi S, Tasaki T, Nabeshima A, Noguchi H, Wang KY, Shimajiri S, Nakano R, et al: Polypeptide N-acetylgalactosaminyl transferase 3 independently predicts high-grade tumours and poor prognosis in patients with renal cell carcinomas. Br J Cancer. 109:472–481. 2013. View Article : Google Scholar : PubMed/NCBI